Read the full article (PDF) >
Law360, New York (April 5, 2013) --The Federal Trade Commission has spent the better part of a decade pressing an expansive view of antitrust law in the context of patent settlement agreements between branded and generic pharmaceutical companies, culminating in last week’s oral argument in FTC v. Actavis at the Supreme Court, where it met with a skeptical audience. Now, the FTC has entered previously uncharted ground by filing an amicus brief in a case addressing another issue of importance to the pharmaceutical industry: generic access to branded products for purposes of making Hatch‐Waxman patent challenges.
The articles on our Website include some of the publications and papers authored by our attorneys, both before and after they joined our firm. The content of these articles should not be taken as legal advice.